Modular Medical Inc (MODD)

Modular Medical Delivers Insulin to First Patients on Pivot Tubeless Insulin Patch PumpJune 30, 2026 9:15 AM
ACCESS NewswireFirst Patients Began Device Training and Insulin Delivery Today, Marking Transition to a Commercial CompanyPivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin-Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion-Dollar MarketSAN DIEGO, CO / ACCESS Newswire / June 30, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings.This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical's commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization."Today represents a defining moment for Modular Medical," said Jeb Besser, Chief Executive Officer of Modular Medical. "For the first time, patients are using Pivot to manage their insulin therapy, validating our vision of creating a simpler, more accessible pump solution for people who have historically remained on multiple daily injections. This is only the beginning of our efforts to address this substantial market opportunity, and we look forward to gathering real-world data and feedback, as we seek to scale adoption and achieve long-term growth."For more information on the Pivot system, visit the dedicated site: PivotPump.com and YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.About Modular MedicalModular Medical, Inc. (NASDAQ:MODD) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product; successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.Company Contact:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
IR@modular-medical.comInvestor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KSCA.comSOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Modular Medical Delivers Insulin to First Patients on Pivot Tubeless Insulin Patch Pump

Modular Medical Announces Shipment of Pivot Tubeless Patch PumpsJune 26, 2026 7:58 AM
ACCESS NewswirePivot starter kits are now shipping to multiple endocrinology practicesSAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months.This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin.The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across select metropolitan markets by late 2026.For more information on the Pivot system, visit the dedicated site: PivotPump.com and YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product; the Company's commercial deployment plan and its ability to increase the number of practices offering the Pivot product to patients; successful development of Modular Medical's proprietary technologies; whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products; whether Modular Medical can successfully manufacture its products at high volumes; and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.About Modular MedicalModular Medical, Inc. (Nasdaq:MODD) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.Company Contact:Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.comInvestor Contact:Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KSCA.comSOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps

Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial ExpansionJune 24, 2026 8:17 AM
ACCESS NewswireThe Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in AprilPivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar marketCommercial expansion activities are expected to begin in Q4 2026 SAN DIEGO, CA / ACCESS Newswire / June 24, 2026 / Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company's transition to a commercial-stage medical device company.As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required - all while maintaining clinical accuracy and connectivity."Reaching commercial availability is a transformational milestone that marks Modular Medical's transition from a development-stage company to a revenue-generating commercial business," said Jeb Besser, Chief Executive Officer of Modular Medical. "As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper' population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders."Pivot is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group, which the Company calls the "almost-pumpers," represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across multiple metropolitan markets by late 2026.For more information on the Pivot system, visit the dedicated site: PivotPump.com and the YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product, whether the Company will have initial users by June 30, 2026, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.About Modular MedicalModular Medical, Inc. (Nasdaq: MODD) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.Company Contact:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.comInvestor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KSCA.comSOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch." Featuring Modular Medical CEO - Friday, May 1, 2026April 29, 2026 8:30 AM
ACCESS NewswireMeet with Modular Medical CEO Jeb BesserThere are 4.8 million individuals with diabetes in the US that require daily insulin. Only 20% currently use an insulin pump.Discover Modular Medical's Pivot, the first FDA-cleared, two-part tubeless patch pump featuring a removable 3 mL reservoir, disposable battery, smartphone connectivity for bolus and monitoring, and true electronic accuracy without tubes or constant wear and its associated commercial & manufacturing timeline.Register at MODD-May-Watch.TribePublic.comSAN DIEGO, CA / ACCESS Newswire / April 29, 2026 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a leader in innovative, patient-centric insulin delivery, today announced that Jeb Besser, CEO of Modular Medical, will present at Tribe Public's Webinar Presentation and Q&A Event titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch." The event is scheduled to begin at 8 a.m. pacific / 11 a.m. eastern on Friday, May 1, 2026. To register to join the complimentary event, please visit the Tribe Public LLC at MODD-May-Watch.TribePublic.com. Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.About Modular MedicalModular Medical, Inc. (NASDAQ:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond "superusers" and providing "diabetes care for the rest of us."Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pumpMore information is available at https://modular-medical.com.Pivot is a trademark of Modular Medical in the United States. All trademarks mentioned herein are the property of their respective owners.ABOUT TRIBE PUBLIC LLCTribe Public LLC, headquartered in San Francisco, California, is a distinguished organization that facilitates corporate sponsored global webinars and in-person meetings events across 41 premier venues throughout the United States. Tribe Public's events are tailored to address topics of significant interest to its members, with a particular emphasis on providing direct access to management teams and leading experts from diverse sectors who seek to enhance awareness of their products, achievements, and strategic initiatives. The Tribe's membership is composed primarily of Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and media professionals, all of whom benefit from exclusive opportunities for business development, community building, and informed dialogue in a collegial setting. Members are actively encouraged to shape the event agenda by submitting speaker and company preferences through Tribe Public's complimentary "Wish List" process on its website, ensuring that the programming reflects the evolving interests of its sophisticated community. To learn more about Tribe Public's offerings and to participate in upcoming events, visit their website at: http://www.tribepublic.com/CONTACT:Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.comSOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch." Featuring Modular Medical CEO - Friday, May 1, 2026

Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common StockApril 19, 2026 7:50 PM
ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / April 19, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering (the "Offering") consisting of 750,000 shares of the Company's common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.Maxim Group LLC is acting as the sole placement agent in connection with the Offering.The securities are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-287313), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 22, 2025. The Offering will be made only by means of a prospectus supplement and the accompanying prospectus that form a part of such registration statement. A prospectus supplement relating to the Offering will be filed by the Company with the SEC. When available, copies of the prospectus supplement and accompanying prospectus can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, via email at Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the closing of the Offering; the Company's ability to convert patients to use its Pivot pump product; successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.CONTACT:Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741SOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock

Modular Medical Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 16, 2026 8:00 AM
ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for the last 10 consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.About Modular MedicalModular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.comSOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Two MAJOR catalysts coming:

(1) FDA Clearance on the Pivot.
(2) Commercial LAUNCH of the Pivot.

Recent 'funders' (~68M shares to ~2.3M shares, 1:30 RS) holding through the reverse split will inherit a small FLOAT/OS and HUGE news 😺. "The reverse stock split will reduce the number of outstanding shares of the Company's common stock from 139,810,797 shares pre-reverse split to approximately 4,660,360 shares post-reverse split." Current price 16¢, post split $4.80 (Keep an eye open for an entry, split is at 5:30am ET on March 31, 2026, Tuesday.)


This may be AI generated, not sure.

$MODD

Modular Medical Announces 1-for-30 Reverse Stock SplitMarch 26, 2026 4:05 PM
ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), an innovative insulin delivery technology company, today announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock. The reverse stock split will become effective at 5:30am ET on March 31, 2026. The common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market ("Nasdaq") under the same symbol "MODD" when the market opens on March 31, 2026, with the new CUSIP number 60785L306.The reverse stock split was approved by the Company's shareholders at the Company's fiscal 2026 Annual Meeting, held on January 23, 2026. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on Nasdaq. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from 139,810,797 shares pre-reverse split to approximately 4,660,360 shares post-reverse split.The number of authorized shares of common stock and the par value per share will remain unchanged. As a result of the reverse stock split, every 30 shares of the Company's pre-reverse split common stock will be combined and reclassified into one share of common stock, as applicable. Proportionate voting rights and other rights of such holders will not be affected by the reverse stock split. Holders of fractional shares will be paid cash in lieu of shares.All equity awards outstanding and common stock reserved for issuance under the Company's equity incentive plans and warrants outstanding immediately prior to the reverse stock split will be appropriately adjusted by dividing the number of affected shares of common stock by 30 and, as applicable, multiplying the exercise price by 30, as a result of the reverse stock split.The Company's transfer agent, Colonial Stock Transfer Co., Inc., is acting as exchange agent for the reverse stock split and will send instructions to shareholders of record regarding the exchange of certificates for common stock for uncertificated shares of common stock. Shareholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to the brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.Additional information about the reverse stock split can be found in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission (the "SEC") on January 8, 2026. The Proxy Statement is available at www.sec.gov or at the Company's website at www.modular-medical.com.Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the timing of the Company's reverse stock split; successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services; anticipated consumer demand for the Company's products; general economic, and industry or political conditions in the United States or internationally; and the occurrence of future events or circumstances, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.About Modular MedicalModular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. The Company's mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.comSOURCE: Modular Medical, Inc.View the original press release on ACCESS NewswireOriginal: Modular Medical Announces 1-for-30 Reverse Stock Split

MODD.................................https://stockcharts.com/sc3/ui/?s=MODD&p=W&b=5&g=0&id=p86431144783

25s coming back up, FDA approval may get us over a buck, deadline for NASDAQ compliance is June 29th (bid price over $1)...

I just got a news alert,only thing I see is an offering (8k filing on the 6th)

Why is it that we see all these trades with just one share?

Keep an eye on the DILUTION pressure.
Funders are getting the shares @ .0881 per share. 9¢.

FDA Approval should be coming within a month or two. Initial questions from FDA, if any, probably soon, this month, next week perhaps.



$MODD

Me too 🙂👍️ You're welcome. GLT us. $MODD

I really hope so💪🤩🙏 tanks for your thoughts💪 

Get in @ funder's price...OVERSOLD, FDA approval announcement
will blow this out of the water with MAXIM orchestrating 😺



$MODD

SEC EFFECT was published yesterday. Good to go. 😺

https://www.google.com/search?q=when+is+%24MODD+anticipating+FDA+approval+for+the+Pivot+Pump&rlz=1C1VDKB_enUS1021US1022&oq=when+is+%24MODD+anticipating+FDA+approval+for+the+Pivot+Pump&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCjM0OTI3ajBqMTWoAgiwAgE&sourceid=chrome&ie=UTF-8

Looking for it to correct from an oversold position...Pehaps .25 over a few days, hopefully. Not doing much today, would like to see .18 and above. FDA approval could come any day AFTER the EFFECT from the SEC, I'd imagine. Q1 starts April1. See this PR >> https://finance.yahoo.com/news/modular-medical-achieves-key-manufacturing-133000481.html

What is your guess for tomorrows trade on this🙉🫣?

Hi .1799...8.1M volume.

BOUNCED GREEN! .1184 to .1657. 😸 BRUTAL.

Zero bid support. 3M volume x .20 vwap is only $600,000...

We are offering on a best-efforts basis up to $12,000,000 of shares of our common stock, or up to 23,571,007 shares of common stock, par value $0.001, or “common stock”, and accompanying warrants to purchase up to 23,571,007 shares of common stock, or the “common warrants”, pursuant to this prospectus. The assumed combined public offering price for each share of our common stock, together with a common warrant to purchase one share of common stock, is $0.5091, which represents the last reported sale price of our common stock as reported on the Nasdaq Capital Market on February 19, 2026. Each common warrant will have an exercise price of $ per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the date of issuance. The shares of our common stock and the common warrants are immediately separable and will be issued separately, but will be purchased together in this offering. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the common warrants.

We are also offering pre-funded warrants to purchase up to an aggregate of 23,571,007 shares of common stock, or the “pre-funded warrants” (together with the common warrants, the “warrants”), in lieu of shares of common stock to those purchasers whose purchase of shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock following the consummation of this offering. A holder of pre-funded warrants will not have the right to exercise any portion of its pre-funded warrants if the holder, together with its affiliates and certain related parties, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each pre-funded warrant is exercisable for one share of our common stock. Each pre-funded warrant is being issued together with the same common warrant described above being issued with each share of common stock. For each pre-funded warrant that we sell, the number of shares of common stock that we are selling will be decreased on a one-for-one basis. The assumed combined public offering price of each pre-funded warrant, together with the accompanying common warrant, is $0.5081, which represents the last reported sale price of our common stock as reported on the Nasdaq Capital Market on February 19, 2026 minus $0.001, which will be the per share exercise price of each pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The pre-funded warrants and the common warrants are immediately separable and will be issued separately, but will be purchased together in this offering. In this prospectus, we refer to the common warrants and pre-funded warrants together as the “warrants.” This prospectus also relates to the offering of common stock issuable upon exercise of such warrants. We collectively refer to the shares of common stock and warrants offered hereby and the shares of common stock underlying the warrants as the “securities.”

We have engaged Maxim Group LLC (the “placement agent” or “Maxim”) to act as our exclusive placement agent in connection with this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay the placement agent the fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus.

$MODD

😾 Loading .16s...damn...bad news coming?

OS 78M Volume 3.2M 😺 See what shakes out here...



$MODD

Thanks g,appreciate you greatly!
Psar (parabolic stop and resistance) weekly chart ,flipped to bullish/buy for the first time since Oct 1 bear trend began ,accumulation started Oct 27th,many other indicators pointing up,awaiting fda approval (they are confident enough to begin pre manufacturing,to be ready)

MODD...................................https://stockcharts.com/sc3/ui/?s=MODD&p=d&yr=0&mn=3&dy=0&id=p11960084343

Based on this chart,looking at daily on 1st of year,adx and macd green lines crossed to bullish and it ran for days ,looks same start 3 days now,we shall see if the past shows the future

Maybe there’s a reason it’s unfound,lol

Unfound with only 4 watchers here and 695 on s t

.50 filled

Feb 4 news https://investorshub.advfn.com/stock-market/NASDAQ/modular-medical-MODD/stock-news/97758644/modular-medical-achieves-key-manufacturing-milesto

MODD.51 insulin pump patch awaiting fda approval,3 month breakout(19%untill sma200 breakout),last 2 days running up bolie, strong bullish macd (macd just flipped bullish on monthly!)
25% of daily average volume in pre mkt
Good skill everyone!

First buy .5468,shares to short dropped from 6.2m on the 18th to 3.8M on 18th at close,awaiting to see today’s numbers but demand is growing and it’s starting to move freely with no endless supply added,fda approval might be inbound as expected

https://investorshub.advfn.com/stock-market/NASDAQ/modular-medical-MODD/trades

70s should be douable 

Starting to gain some momentum?

MODD...................................https://stockcharts.com/sc3/ui/?s=MODD&p=W&b=5&g=0&id=p86431144783

MODD, reports Monday 6/16

Tiger Money, check these out >> 3 Multibaggers on RADAR

No doubt as this will go on a run.  Let's please keep each other informed on our dd for this name as time passes.  Thanks and have a great weekend!

Good move. Keep an eye on it. They said LAUNCH was to be early 2025.
I consider early to be 1st quarter. Hopefully LAUNCH by end of March.
See what they say in the Annual Meeting tomorrow.

JMO GLTY

$MODD

I had to bail around $1.20 as the pain got too much.  Company is for sure undervalued 

Whoa, she fell below .90, Tiger Money. Still adding. Annual Meeting tomorrow.
Surprised it's sold off this much on such low volume...but happily adding.
GLTY (us)



Sell off on very low volume. OS is approximately 41 million.



$MODD

Great information!  Thank you brother!  I'm long and strong and waiting for that pop!  It will go parabolic seven volume finally comes in on "our" 12.50 day!  Good luck!

Scooping up these sub 1.30s. See article below...

Launch (already FDA cleared) in the US is "early 2025"...that means soon to me. Fine. Still accumulating. CE mark for EU in 2026.

👉️ https://www.drugdeliverybusiness.com/modular-medical-step-forward-ce-mark/

Current Price 1.25. 10 bagger in a year. 12.50. Probably faster. JMO

$MODD

Any new thoughts here?  Thanks 

Thank you so much!

Yes I do, Tiger Money 😺

I would buy as much as I could of this the only restraint being the unpredictability of the USCOG (US communist occupation government) leading up to the 2024 election and shortly thereafter...February 2025...

In "normal times" load the boat here, JMO

👉️ https://ir.modular-medical.com/data/files/ModularMedical-InvestorPresentation-September-10-2024.pdf

$MODD @ 2.37